The Summary of Product Characteristics (SmPC) for Dymista lists epistaxis, headache, dysgeusia (unpleasant taste), unpleasant smell as very common or common adverse reactions.6
Please refer to the Summary of Product Characteristics (SmPC) before prescribing, particularly in relation to adverse reactions, precautions, contra-indications and method of use.
- Meltzer E, et al. Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis. Int Arch Allergy Immunol. 2013; 161(4): 369-377.
- Price D, et al. MP29-02 a novel intranasal therapy for the treatment of chronic rhinitis: safety data from a 12 month-trial. Presented at EEAACI, Geneva, 16-20 June 2013.
- Carr W, et al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol. 2012; 129(5):
- Hampel FC, et al. Double-blind, placebo-controlled study of azelastine and fluticasone in a single nasal spray delivery device. Ann Allergy Asthma Immunol. 2010; 105(2): 168-173.
- Bousquet J, et al. Onset of Action of the Fixed Combination Intranasal Azelastine-Fluticasone Propionate in an Allergen Exposure Chamber.
J Allergy Clin Immunol Pract. 2018; 6(5): 1726-1732.
- Dymista® Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/9450. Last accessed: November 2023.
- Scadding GK, et al. BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis (Revised Edition 2017; First edition 2007). Clin Exp Allergy 2017; 47(7): 856-889.
- Scottish Medicine Consortium (SMC). Available at: https://www.scottishmedicines.org.uk/medicines-advice/azelastine-hydrochloride-plus-fluticasone-propionate-dymista-abbreviatedsubmission-92113/. Last accessed: November 2023.
- Brożek JL, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. 2017; 140(4): 950-958.
- Lipworth B, et al. An algorithm recommendation for the pharmacological management of allergic rhinitis in the UK: a consensus statement from an expert panel. NPJ Prim Care Respir Med. 2017; 27(1): 3.